Swiss Biotech – an Overview

South Korea – Swiss Biotech – www.swissbiotech.org

Swiss Biotech Association

Domenico (Nic) Alexakis - CEO

Young Industry

1953 – Nobel Price for Double Helix Crick/Watson

Memorandum of Understanding

Agenda

▸ Introduction – Stakeholders

▸ Latest Statistics (Swiss Biotech Report 2016/OECD 2012)

▸ SBA – Issues and Activity Fields

▸ Focus: Digital Health

Introduction:

Definition of Biotechnology, the OECD Colour Code

▸ White Biotechnology (industrial BT) ▸ Fermentation and biotransformtion of chemicals and natural products & raw materials.

▸ Red Biotechnology (pharmaceutical BT)▸ Development and production of (bio)pharmaceuticals, vaccines and diagnostics.

▸ Grey Biotechnology (environmental BT)

▸ Identification and decontamination of harmful products.

▸ Blue Biotechnology (marine BT) ▸ Use of marine organisms for pharmaceuticals, nutrition, cosmetics and new materials.

▸ Green Biotechnology (agricultural BT) ▸ Transgenic plants for nutrition and as renewable raw materials for sustainable chemistry.

OECD defines of biotechnology as

‚the application of science and technology to living organisms, as well as parts,

products and models thereof to alter living or non-living materials for the production

of knowledge, goods and services.

Main Players in Swiss BiotechStrategic Level / Structures

SNSF & KTI/CTI

Funding Agencies

Scienceindustries

Swiss Society of

Chemical Industries

SKB / SCCB

Swiss Coordination

Committee for

Biotechnology

Universities

ETHZ / EPFL

UoAppl.Sc.

SBA

Swiss Biotech Association

SAMS & SATW

& SCNAT

Swiss Academies

SIBC

Swiss Industrial

Biocatalysis

ConsortiumBiotechnet

SwitzerlandBiotech Sector

Switzerland

Internutrition

Interpharma

Main Players in Swiss Biotech Promotion (e.g. Swiss Biotech Report)

Statistic Supplier

E & Y Switzerland

CTISwiss Innovation

Promoation Agency

IGESwiss Federal Institute

of Intellectual Property

swiTTSwiss Technology

Transfer

Association

SBASwiss Biotech

Association

S-GEBusiness Network

Switzerland

-----------------------------

Region Clusters

Biotechnet Switzerland

SIXSwiss Exchange

SNSFSwiss National Science

Foundation

S.E.C.A.Swiss Private Equity

& Corporate Finance

Association

History of SBA

▸ VSBU/ASBC founded March 1998 – vote on gene technology

▸ Renamed to Swiss Biotech Association in June 2003

▸ In 2002/03 Biotechnology, a topic with economic development

▸ In 2003 creation of SLSMA (Marketing organisation) – end 2011

▸ Always contact/projects with osec, now S-GE

1Nation1Cluster – Regional Clusters

BaselArea (1/2)

▸Main Industry

▸ Life Sciences: Novartis, Roche, Syngenta, Lonza, Bachem

▸ Chemistry: Carbogen Amcis, Clariant, Huntsman, Solvias

▸ Logistics: DHL/Danzas, Panalpina, Rhenus

▸Key Academic Institutions

▸ University of Basel with Biozentrum

▸ University Hospitals of Basel

▸ ETH Zürich in Basel (Biosystems Science and Engineering)

▸ Swiss Nanoscience Institute, Basel

▸ Friedrich Miescher Institute for Biomedical Research (FMI)

▸ Swiss Tropical and Public Health Institute

▸ University of Applied Sciences Northwestern Switzerland

▸ Initiative: www.baselarea.ch

▸Specialities

▸ International Exhibition and Congress Center (e.g. SBD, MipTec, Ilmac)

▸ Technologiepark Basel with university start-up incubator

▸ „Flagships“(selection)

▸ NBE Therapeutics - Actelion Pharmaceuticals Ltd.

▸ Basilea Pharmaceutica AG - Evolva Holding

▸ 4-antibody AG - Santhera Pharmaceuticals

▸Competitive Advantages

▸ Proximity to Germany and France

▸ “Big Pharma” Connections

▸ High concentration of customs research and manufacturing organizations,

engineering and suppliers

▸ Active Technopark

BaselArea (2/2)

▸Main Industry

▸ Life Sciences, Engineering and ICT

▸ Services and HQ’s

▸ Banking – Stock Exchange SIX

▸Key Academic Institutions

▸ University of Zurich

▸ Federal Institute of Technology (ETHZ)

▸ Universities of Applied Sciences (Wädenswil, Winterthur)

▸ University Hospitals Zürich

▸ lifescience zurich with competence centres, e.g. Functionals Genomics

Center, NCCR Structural Biology, TEDD, SystemsX

▸ Initiative: www.greaterzuricharea.ch

Greater Zürich Area (1/2)

▸Specialities

▸ BIO-TECHNOPARK Schlieren-Zürich

▸ Conferences and Life Sciences seminars

▸ Focused Investment conferences (SACHS)

▸ „Flagships“(selection)

▸ ESBATech / Delenex - Glycovaxyn

▸ Neurotune - Kuros Biosurgery

▸ Molecular Partners AG - Neurimmune Holding AG

▸ Prionics AG - SIX – Swiss Exchange

▸Competitive Advantages

▸ global initiative

▸ internationalisation

▸ financial community

▸ Active technopark

Greater Zürich Area (2/2)

▸Main Industry

▸ Chemical and pharmaceutical

▸ Banking

▸ Textile

▸ Tourism

▸Key Academic Institiutions

▸ Università della Svizzera Italiana, Accademia di architettura

▸ University of Applied sciences

▸ Institute for Research in Biomedicine

▸ Istituto Oncologico della Svizzera Italiana

▸ Istituto delle Molle per la ricerca sull’intelligenza artificiale

▸ Centro Svizzero di Calcolo Scientifico

▸ Initiative: www.biopolo.ch

Biopolo Ticino (1/2)

▸ Specialities

▸ Strong manufacturing and services cluster

▸ Strong clinical settings (public and private)

▸ „Flagships“ (selection)

▸ Cerbios AG - Helsinn SA

▸ Humabs Sagl - IBSA Institut Biochimique S.A.

▸ Micro-Sphere SA - Telormedix SA

▸ Competitive Advantages

▸ Competitive position for research in human immunology

▸ Proximity to Italy

▸ Quality of life

Biopolo Ticino (2/2)

▸Main Industry

▸ Microelectronics / Life Sciences

▸ Watches

▸ Private Banking

▸Key Academic Institiutions

▸ University of Geneva / Lausanne (HUG/CHUV)

▸ Swiss Federal Institute of Technology (EPFL)

▸ Swiss Institute for Cancer Research Ludwig Institute

▸ Swiss Institute for Bioinformatics (SIB)

▸ ISREC, Lausanne

▸ University Hospitals

▸ Initiative: www.bioalps.com

bioalps (1/2)

▸Specialities

▸ joint efforts of academic institutions in Life Sciences

▸ Technoparks / incubators (e.g. Biopôle, Eclosion, Park Scientifique)

▸ „Flagships“ (selection)

▸ AC Immune - Addex

▸ Debiopharm Group - Glenmark

▸ Mymetics - NovImmune

▸ Campus Biotech - Baxter

▸Competitive Advantages

▸ multi-disciplinary research activities (NCCR’s)

▸ international environment

▸ proximity to France

▸ quality of life

bioalps (2/2)

18

Funding Partners in the Innovation Process

Source: SNF, CTI

19

CTI Promotion Instruments

Source: CTI

Split of publications with international collaboration

Swiss Personalised Health Networkend of 2016 in action

Agenda

▸ Introduction – Stakeholders

▸ Latest Statistics (Swiss Biotech Report 2016/OECD 2012)

▸ SBA – Issues and Activity Fields

▸ Focus: Digital Health

Swiss Biotech Association – The voice of Biotech

24

Biotech start-ups form 1995 - 2010

Source: Swiss Biotech Report 2011

Results ofSPP Biotech

Global map of science

Source: Rafols et al., 2010

The Swiss Biotech structure of relationship for the

pharmaceutical-diagnostic industry and health care

Source: NTN Swiss BiotechTM, 2016

NCCR facilitate exchanges within Swiss research

National Competence Centers for Research

Source: SNF, 2016

Stakeholders in the drug innovation process

Source: Swiss Biotech Association, 2016

Global pharma sales trends and outlook

Source: EY, Capital IQ, IMS Health, and company financial data, 2016

Number of biotech companies in Switzerland

Workforce 2013 – 2016 (OECD Report/study)

Capital investment in Swiss biotech companies

Financial data of Swiss biotech companies

Page

Life Sciences on SIX Swiss Exchange

Peer group

14/07/2016 34Zurich,

HealthCare ProvidersMedtechPharma Biotech

Steering committee of the Swiss Biotech Report 2016issued since 2003

Domenico Alexakis Seraina Benz Oreste GhisalbaFlorian Fisch

Liv MinderJan Lucht Jürg ZürcherHeinz Müller

International Dedicated Biotech Companies

Cluster Density

Basel: 65Zurich: 79

Vaud/GVA 75

Agenda

▸ Introduction – Stakeholders

▸ Latest Statistics (Swiss Biotech Report 2016/OECD 2012)

▸ SBA – Issues and Activity Fields

▸ Focus: Digital Health

The Swiss Biotech Association

▸ Development of optimal framework conditions for the biotech sector:

▸ Representation of the biotech interests to policy makers

▸ Networking of stakeholders at national and international level:

▸ Through the development anbd maintenance of biotechnology-specific platforms

▸ Organisation and participation at national and international events

▸ Dissemination of accomplishments in biotechnology:

▸ To the political audience and the general public

▸ Increase of the visibility at national and international level

▸ Collaboration with strategic partners:

▸ As a member of national and international umbrealla organisation

▸ Through collaborations with life science clusters / initiatives

▸ Broad support form Swiss Biotech companies:

▸ 80% of all Biotech companies in Switzerland are members

Further Activity Fields

▸ Strengthening lobbying capabilities by combining Pharma

and biotech interests, e.g. Regulatory hurdles in CH

▸ Fostering collaborations among biotech, medtech and

pharma

▸ Promoting natural sciences as education & Research

fields

▸ International public affairs

▸ Technology Transfer

Summary - Innovation Instruments CH

26.03.2013 | © SWITZERLAND GLOBAL

ENTERPRISE

Idea Research Development Production Distribution

SNF

CTI projects

CTI Invest

Research Funding

IP Protection

TTStart-up

Pre-clinical

CTI Start-up

Clinical Lead / Target Identification

Proof ofConcept

NDA

SeedFunding

VCPharma

DistributorsAffiliates

Osec

Logistics, Site Investment

AcademiaETH / EPFL, Universities,

Universities of Applied Sciences

IndustryPrivate-Public Partnerships

SwittIPI, WPO

IPIWPO

Swissmedic(Inspection)

SwissmedicEMA FDA

Public Health

Legal ServicesTTOs

Legal ServicesConsultants

Contract R&DBioIT, Suppliers

ClinicalROs

CMOsEquipment suppliers

Engineering

Legal ServicesConsultants

LogisticsMarketing

Organizations

Regulatoryconsultants

Analytical LabsSuppliers

221 SBA-Members (1Q 2016, multiple entries possible)

SBA – split of member activities

«SWISS Pavilion» at BIO

BIO since 1999 with

a Swiss Pavilion – 2016 S.F.

European Biotech Week 2016

2016 – September 25 – October 1, Fall Day on Sept.29

Industrial Biotechnology: Cleantech by Biotech

scienceindustries and Swiss Biotech Association have joined forces to create awareness and develop supportive measures for Cleantech by Biotech in the Swiss chemical-pharmaceutical industry.

Submission of a proposal for a new National Research Program NPF „Cleantech by Biotech“ (June 2011)

Event „Cleantech by Biotech“ (2012)

ProductsProtein, sugar and DNA building

blocks, vitamins, flavors, fragrances and dyes, biopharmaceuticals and

biomaterials, etc.

Technologies & Tools

Communication - Technology Transfer - Education

Sustainable Production

Precursors & raw

materials

How?

Euresearch an association mandated by government

and financed through SBFI

Eursearch is active in promotion and support of project

applicatns.

The SBFI ordinance expected in October 2014 will

organize how the financing of Swiss partners in

collaborative projects (also SMEs) will be managed.

Euresearch is the National

Contact Point for the EEN

Network (Technology Offers &

Requests & Partnering)

Euresearch promotes and informs about

European programmes such as cost,

EUREKA, eurostars, ERA-Net.

The program organization is within SBFI.

Regional offices

Eurostars runs regional offices at

all major universities and

universities of applied sciences

for local support.

Swisscore Brussels

Euresearch is partner of

Swisscore in Brussels.

Agenda

▸ Introduction – Stakeholders

▸ Latest Statistics (Swiss Biotech Report 2016/OECD 2012)

▸ SBA – Issues and Activity Fields

▸ Focus: Digital Health

Focus Digital Health

▸ Definitions

▸ Examples with Swiss connections

▸ Examples of other countries

Digital Healthcare courtesy of wikipedia

Digital Health courtesy of wikipedia

A personal health record, or PHR, is a health record where health data and information related to the care of a patient

is maintained by the patient.[1] This stands in contrast to the more widely used electronic medical record, which is

operated by institutions (such as hospitals) and contains data entered by clinicians or billing data to support insurance

claims. The intention of a PHR is to provide a complete and accurate summary of an individual's medical history which

is accessible online. The health data on a PHR might include patient-reported outcome data, lab results, data from

devices such as wireless electronic weighing scales or collected passively from a smartphone

Wearables ? eHealth

Digital Health sorgt für Dynamik

16.04.2016

Finanz und Wirtschaft

(Copyright ©2009, Dow Jones & Company Inc.) Neue Anbieter mischen den Markt für Gesundheitsleistungen auf. Fitnessarmbänder boomen. Garmin und Fitbit bieten die Geräte in Massen an. Auch die smarten Uhren, die auf den Betriebssystemen von Apple und Alphabet (ehemals Google) basieren, ­liefern entsprechende Funktionen. Sportbegeisterte können so den Kalorien­verbrauch und die

zurückgelegte Strecke nachverfolgen. Der wahre Nutzen liegt ­jedoch in den Daten, die so generiert ­werden und mit denen sich Rückschlüsse auf den Gesundheitszustand ziehen ­lassen. Das Schlagwort heisst Digital Health. «Im Gesundheitssystem liegt die Zukunft in der Digitalisierung», ist sich Stefan Blum, Medtech-Portfolio-Manager des Fondsanbieters Bellevue Asset Mana­gement, sicher. Fitnessarmbänder sind nur der erste spielerische Schritt dazu. Die Unternehmen aus dem Gesundheitssektor haben die Digitalisierung lange verschlafen. Neue

innovative ­Akteure drängen deshalb in den Markt. Ziel ist längst nicht mehr nur der Wellness-Bereich. Die «jungen Wilden» versuchen sich speziell in der Diagnostik und in der Überwachung von Patienten zu etablieren. Neue digitale Ansätze in diesen Disziplinen könnten das

Gesundheitssystem insgesamt effizienter machen. Die Anbieter wiederum erhalten zusätzliche Daten, die sich zu Wissen verarbeiten lassen. «Mehr Wissen führt zu mehr Innovation, und Innovation bedeutet einen Wett­bewerbsvorteil», sagt Blum.

Gefragt sind Kooperationen Ganz ohne Hilfe schaffen es die Herausforderer dann aber doch nicht. IT-Spezialisten sind auf das Fachwissen aus dem Gesundheitssektor angewiesen. Umgekehrt fehlt der Gesundheitsbranche das Know-how für die Verarbeitung von Daten zu Informationen. Vertreter aus beiden Sektoren arbeiten deshalb zusammen. So unterhält Alphabet heute mit den Pharmakonzernen Novartis und

Sanofi Partnerschaften mit dem Ziel der Entwicklung neuer permanenter Überwachungslösungen von Diabetespatienten. Doch Alphabets Vision greift weiter. Die Gesellschaft hat mit ihrer eigens gegründeten Life-Science-Sparte auch den Diagnostikmarkt im Visier. Sie arbeitet mit bislang ungenannten Partnern an einer Technologie, die dereinst Gene in Echtzeit entschlüsseln soll und konkurrenziert so Roche, den Primus in der Labordiagnostikbranche. Damit ist der gleich doppelt gefordert. Das US-Unternehmen

Illumina ist den Schweizern seit geraumer Zeit mit ihren Hochgeschwindigkeits-Gensequenzierungsgeräten technologisch voraus (vgl. Artikel links).

Krebstest für alle Nun geht Illumina sogar noch einen Schritt weiter. Sie hat im Januar die Gesellschaft Grail

gegründet, angelehnt an den Heiligen Gral, den es in der Onkologie zur Heilung zu finden gilt. Bis 2019 will Grail einen neuen Bluttest zur frühzeitigen Identifikation aller möglichen krebsverursachenden Genmutationen entwickeln. Damit könnten künftig standardmässig bereits vermeintlich gesunde Patienten auf die Gefahr einer Krebserkrankung ­getestet werden. Das Projekt ist angesichts der Zeitspanne zwar ambitioniert. Würde es jedoch gelingen, wäre letztlich nicht nur Roche gefordert, sondern auch die Anbieter bildgebender Diagnostik wie Siemens oder Philips. Deren Geräte wären dann ebenfalls weniger gefragt.

Illumina kann bei Erfolg jedoch nicht nur den Absatz ihrer eigenen Geräte steigern: «Die Technologie generiert auch eine Vielzahl an zusätzlichen Daten, die potenziell Rückschlüsse auf neue Behandlungsansätze zulassen», sagt Blum. Sie könnten dann teuer an die Pharmakonzerne verkauft werden. Roche hat das als einer der wenigen Arzneimittelhersteller erkannt. Die Gesellschaft versucht deshalb durch den Zukauf von Krebsdatenplattformen wie Foundation

Focus Digital Health

▸ Definitions

▸ Examples with Swiss connections

▸ Examples of other countries

Swiss Connections – Big data: Roche, Novartis, Merck

and innovative SME’s

▸ Digital transformation is happening now:

▸ Merck optimises production failures with Hadoop

▸ Novartis cooperates with google

▸ Roche strategically with Foundation Medicine (FM) (57%)

▸ GE JV with ETHZ www.inspection-robotics.com

▸ www.sequanamidecal.com

Dacadoo

Swiss Start-Ups

3D-print

Bioprinting

Industrial applications

ShortList

Alpha SprachweltAXA WinterthurInterioSanitasSwiss LifeVictorinoxWincasa

Organiser of the competition

Focus Digital Health

▸ Definitions

▸ Examples with Swiss connections

▸ Examples of other countries

Smart scalpel knows the difference between healthy and

tumorous tissue – April 2016

The smart scalpel has been tested on artificial tissue with what the researchers claim to be

excellent results.

For a brain surgeon, telling tumorous tissue from healthy tissue can be tricky business in the

middle of a procedure, with potentially disastrous repercussions if mistakes are made.

Looking to give these doctors a helping hand, scientists have designed a smart scalpel that

provides real-time guidance on whether the tissue it is tending to is cancerous or otherwise.

The new tool is the same size of a regular scalpel, but features a spherical tip on the end.

Inside are sensors that gauge the mechanical properties of the tissue and, within around 400

milliseconds, present the surgeon with visual or audio cues to indicate its health.

"The technology of the device is based on self-sensing actuators using piezoelectric

transducers," David Oliva, who developed the device at the Belgium's Free University of

Brussels, explains to Gizmag. "The self-sensing actuator generates vibration on the tip of the

instrument. When the device is touching brain tissue, the vibration is induced into the brain

tissue and the device realizes the estimation of the mechanical properties, then this

measurement is compared to a reference value previously taken on a well known healthy area

to determine if there are changes in the consistency of the tissue. The process is, therefore, a

tissue differentiation evaluation."

While MRI and ultrasounds can pinpoint the whereabouts of a brain tumor prior to an

operation, various factors can lead doctors to lose its position once the surgery commences,

especially when dealing with early stage tumors which can look much like healthy tissue. In

this scenario, doctors are left to use microscopic observations or go poking around with tissue

manipulation tools.

In 2013, researchers at the Imperial College London developed a similar knife that uses mass

spectrometry to assess clouds of biological smoke emitted from surgical incisions and sniff

out signs of cancer. And way back in 2000, researchers developed a scalpel that can detect

cancer by searching cell populations for abnormal protein content.

So a tool that offers neurosurgeons a higher level of precision when carrying out these

procedures has been in the works for some time. About six years in the making, this latest

take on the smart scalpel has been used on artificial tumors and pig brain tissue with what the

researchers claim to be "excellent results."

According to Oliva, who developed the scalpel in collaboration with German neurosurgeon

Dr Ralf Stroop, it is designed specifically to tackle early stage brain tumors that are visible

through an MRI but not in the operating room. He says that the technology could also be

adapted to detect tumors in other parts of the body, and that the early testing has demonstrated

its suitability for human trials.

Medical Tricorder

Bypassing spinal cord lets paralyzed man control own

hand courtesy of Nature

While Burkhart's early progress is hugely promising, the

researchers hope that it is just a sign of things to come.

Using a specialized sleeve, his own mind and a brain-implant

smaller than a pea, a man paralyzed from the neck down has

regained the ability to handle a variety of everyday objects. The

researchers say the success of the technology, which bypasses

the injured spinal cord, offers "realistic hope" to others with

similar disabilities, with the team planning to expand the trial to

include new patients in the coming months. After becoming

paralyzed in a diving accident six years ago, 24-year-old Ian Burkhart

volunteered to take part in a trial at Ohio State University to explore the

effectiveness of what is described as a neural bypass system. Dubbed

NeuroLife, the technology involves a tiny micro-chip sensor implanted

into the motor cortex area of the brain, the region responsible for the

movement of arms and hands.

This sensor tracks neural impulses from the brain and is hooked up to

a computer, which uses algorithms to decode and translate them into

electrical signals. These signals are then relayed to a purpose-built

sleeve that contains electrodes to stimulate muscles in the arm.

Burkhart and the NeuroLife system made headlines in 2014, when he

became the first quadriplegic to move his fingers and hand using his

own thoughts. But the hard work didn't stop there, and the progress

Burkhart has made in the meantime is quite remarkable.

While the initial breakthrough gave Burkhart the ability to pick up and

hold a spoon, after hundreds of therapy sessions he can now use the

NeuroLife system to perform a number of tasks, including picking up a

phone, stirring a drink, swiping a credit card and playing a guitar video

game similar to Guitar Hero.

"Several years after a spinal cord injury, his level of

functioning has improved significantly so he's able

to have more use of his fingers and hands to do

functional tasks, which has not been demonstrated

before," says Dr Ali Rezai, who implanted the chip

in Burkhart's brain in 2014.

The more Burkhart uses the system the more it

learns from his brainwaves and the more he learns

to control his movements. And while this early

progress is hugely promising, the researchers hope

that it is just a sign of things to come. They have

identified four other candidates for the NeuroLife

system, the first of which is scheduled to take part

in the study this US summer. Eventually, they hope

to improve the technology to make it less

cumbersome and to assist people who have

suffered strokes and other brain or spinal cord

injuries.

"We're hoping that this technology will evolve into a

wireless system connecting brain signals and

thoughts to the outside world to improve the

function and quality of life for those with

disabilities," says Rezai.

You can see Burkhart using the system in the video

below. The research was published in the journal

Nature.

The Swiss Biotech structure of relationship for the

pharmaceutical-diagnostic industry and health care

Source: NTN Swiss BiotechTM, 2016